ERC Belgium, a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer, has announced promising interim results in the phase 2 clinical trial for ERC1671 under FDA IND 15430 at the University of California, Irvine Medical Center in Orange, California.
August 19, 2020
· 4 min read